Area:
Immunology, Molecular Biology, Cell Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Ji-Won Yoon is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2001 — 2002 |
Yoon, Ji-Won |
R21Activity Code Description: To encourage the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) |
A Gene Therapy For the Treatment of Type 1 Diabetes
DESCRIPTION (provided by applicant) The development of insulin-dependent diabetes mellitus (IDDM) results from the almost total destruction of insulin-producing pancreatic beta cells by beta cell-specific autoimmune responses. The cure of IDDM has long been attempted using methods such as islet transplantation, regeneration of beta cells and insulin gene therapy. However, permanent remission of IDDM has not yet been satisfactorily achieved. We recently developed a recombinant adeno-associated virus (rAAV) that expresses a single chain insulin analog (SIA), which possesses biologically active insulin activity without processing, under the control of the hepatocyte-specific L-type pyruvate kinase promoter (rAAV-LPK-SIA), which regulates SIA expression in response to blood glucose levels. Intraportal venous injection of rAAV-LPK-SIA resulted in the long-term remission of diabetes in streptozotocin (STZ)-induced diabetic rats and nonobese diabetic mice without any apparent side-effects. However, a painful and potentially risky surgical procedure involving a mid-line abdominal incision was required for the delivery of rAAV-LPK-SIA to the liver. The first Specific Aim of this study is to improve this novel gene therapy by replacing the surgical procedure with a simple intravenous injection that does not require surgery. The non-human primate is an ideal model to test this rAAV-LPK-SIA gene therapy for preclinical trials, as they are physiologically and morphologically similar to humans. The common marmoset (Callithrix jacchus) is a non-human primate that is relatively small, inexpensive and easy to handle and breed as compared to other non-human primates. The second Specific Aim of this study is to determine whether the administration of rAAV-LPK-SIA into the STZ-induced diabetic marmoset can express SIA and control blood glucose levels, resulting in the long-term remission of diabetes. The information obtained through these studies will be invaluable for the development of a gene therapy for the cure of human type 1 diabetes.
|
1 |
2005 — 2006 |
Yoon, Ji-Won |
P51Activity Code Description: To support centers which include a multidisciplinary and multi-categorical core research program using primate animals and to maintain a large and varied primate colony which is available to affiliated, collaborative, and visiting investigators for basic and applied biomedical research and training. |
Gene Construct For Diabetes @ University of Wisconsin Madison |
0.964 |